» Articles » PMID: 38137493

Risk Assessment of Psychotropic Drugs on Mitochondrial Function Using In Vitro Assays

Overview
Journal Biomedicines
Date 2023 Dec 23
PMID 38137493
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondria are potential targets responsible for some drug- and xenobiotic-induced organ toxicities. However, molecular mechanisms of drug-induced mitochondrial toxicities are mostly unknown. Here, multiple in vitro assays were used to investigate the effects of 22 psychotropic drugs on mitochondrial function. The acute extracellular flux assay identified inhibitors of the electron transport chain (ETC), i.e., aripiprazole, phenytoin, and fluoxetine, an uncoupler (reserpine), substrate inhibitors (quetiapine, carbamazepine, buspirone, and tianeptine), and cytotoxic compounds (chlorpromazine and valproic acid) in HepG2 cells. Using permeabilized HepG2 cells revealed minimum effective concentrations of 66.3, 6730, 44.5, and 72.1 µM for the inhibition of complex-I-linked respiration for quetiapine, valproic acid, buspirone, and fluoxetine, respectively. Assessing complex-II-linked respiration in isolated rat liver mitochondria revealed haloperidol is an ETC inhibitor, chlorpromazine is an uncoupler in basal respiration and an ETC inhibitor under uncoupled respiration (IC = 135 µM), while olanzapine causes a mild dissipation of the membrane potential at 50 µM. This research elucidates some mechanisms of drug toxicity and provides some insight into their safety profile for clinical drug decisions.

Citing Articles

Aripiprazole, but Not Olanzapine, Alters the Response to Oxidative Stress in Fao Cells by Reducing the Activation of Mitogen-Activated Protein Kinases (MAPKs) and Promoting Cell Survival.

Kramar B, Marolt T, Yilmaz Goler A, Suput D, Milisav I, Monsalve M Int J Mol Sci. 2024; 25(20).

PMID: 39456900 PMC: 11508229. DOI: 10.3390/ijms252011119.

References
1.
Boelsterli U, Lim P . Mitochondrial abnormalities--a link to idiosyncratic drug hepatotoxicity?. Toxicol Appl Pharmacol. 2007; 220(1):92-107. DOI: 10.1016/j.taap.2006.12.013. View

2.
Carnovale C, Lucenteforte E, Battini V, Mazhar F, Fornili M, Invernizzi E . Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med. 2021; :1-13. DOI: 10.1017/S0033291721000180. View

3.
Carbon M, Hsieh C, Kane J, Correll C . Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017; 78(3):e264-e278. DOI: 10.4088/JCP.16r10832. View

4.
Inoue Y, Usui N, Hiroki T, Shimizu K, Kobayashi S, Shimasaki S . Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers. Eur J Drug Metab Pharmacokinet. 2012; 38(2):139-48. PMC: 3664181. DOI: 10.1007/s13318-012-0105-x. View

5.
Dykens J, Jamieson J, Marroquin L, Nadanaciva S, Xu J, Dunn M . In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci. 2008; 103(2):335-45. DOI: 10.1093/toxsci/kfn056. View